FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051223449> ?p ?o ?g. }

• W2051223449 endingPage "e75414" @default.
• W2051223449 startingPage "e75414" @default.
• W2051223449 abstract "Approximately half of tumor cell lines are resistant to the tumor-selective apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (Apo22L/TRAIL). Previously, we showed that combining Apo2L/TRAIL with sorafenib, a multikinase inhibitor, results in dramatic efficacy in Apo2L/TRAIL-resistant tumor xenografts via inhibition of Mcl-1. Soluble Apo2L/TRAIL is capable of binding to several surface receptors, including the pro-apoptotic death receptors, DR4 and DR5, and decoy receptors, DcR1 and DcR2. Monoclonal antibodies targeting either of these death receptors are being investigated as antitumor agents in clinical trials. We hypothesized that sorafenib and Apo2L/TRAIL or Apo2L/TRAIL death receptor agonist (TRA) antibodies against DR4 (mapatumumab) and DR5 (lexatumumab) will overcome resistance to Apo2L/TRAIL-mediated apoptosis and as increase antitumor efficacy in Apo2L/TRAIL-sensitive solid tumors.We found that Apo2L/TRAIL or TRA antibodies combined with sorafenib synergistically reduce cell growth and increase cell death across a panel of solid tumor cell lines in vitro. This panel included human breast, prostate, colon, liver and thyroid cancers. The cooperativity of these combinations was also observed in vivo, as measured by tumor volume and TUNEL staining as a measure of apoptosis. We found that sorafenib inhibits Jak/Stat3 signaling and downregulates their target genes, including cyclin D1, cyclin D2 and Mcl-1, in a dose-dependent manner.The combination of sorafenib with Apo2L/TRAIL or Apo2L/TRAIL receptor agonist antibodies sensitizes Apo2L/TRAIL-resistant cells and increases the sensitivity of Apo2L/TRAIL-sensitive cells. Our findings demonstrate the involvement of the Jak2-Stat3-Mcl1 axis in response to sorafenib treatment, which may play a key role in sorafenib-mediated sensitization to Apo2L/TRAIL." @default.
• W2051223449 created "2016-06-24" @default.
• W2051223449 creator A5002703541 @default.
• W2051223449 creator A5008547275 @default.
• W2051223449 creator A5023976873 @default.
• W2051223449 creator A5032760861 @default.
• W2051223449 creator A5064081956 @default.
• W2051223449 creator A5070384778 @default.
• W2051223449 creator A5070729843 @default.
• W2051223449 creator A5075201353 @default.
• W2051223449 date "2013-09-26" @default.
• W2051223449 modified "2023-10-11" @default.
• W2051223449 title "Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis" @default.
• W2051223449 cites W1535042563 @default.
• W2051223449 cites W1565276921 @default.
• W2051223449 cites W1821858011 @default.
• W2051223449 cites W1976396902 @default.
• W2051223449 cites W1981467511 @default.
• W2051223449 cites W1985355814 @default.
• W2051223449 cites W1987388371 @default.
• W2051223449 cites W1990196512 @default.
• W2051223449 cites W1999468766 @default.
• W2051223449 cites W2006382528 @default.
• W2051223449 cites W2009085926 @default.
• W2051223449 cites W2017749679 @default.
• W2051223449 cites W2018902131 @default.
• W2051223449 cites W2020439083 @default.
• W2051223449 cites W2038444711 @default.
• W2051223449 cites W2045255643 @default.
• W2051223449 cites W2049548558 @default.
• W2051223449 cites W2069875612 @default.
• W2051223449 cites W2070396671 @default.
• W2051223449 cites W2079022408 @default.
• W2051223449 cites W2081804855 @default.
• W2051223449 cites W2094302689 @default.
• W2051223449 cites W2096439168 @default.
• W2051223449 cites W2098491642 @default.
• W2051223449 cites W2098509343 @default.
• W2051223449 cites W2099932018 @default.
• W2051223449 cites W2100274686 @default.
• W2051223449 cites W2117476538 @default.
• W2051223449 cites W2118971842 @default.
• W2051223449 cites W2126277558 @default.
• W2051223449 cites W2138393270 @default.
• W2051223449 cites W2140287543 @default.
• W2051223449 cites W2140765540 @default.
• W2051223449 cites W2147671525 @default.
• W2051223449 cites W2151214205 @default.
• W2051223449 cites W2152251876 @default.
• W2051223449 cites W2158734599 @default.
• W2051223449 cites W2160246583 @default.
• W2051223449 cites W2162606162 @default.
• W2051223449 doi "https://doi.org/10.1371/journal.pone.0075414" @default.
• W2051223449 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3784419" @default.
• W2051223449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24086526" @default.
• W2051223449 hasPublicationYear "2013" @default.
• W2051223449 type Work @default.
• W2051223449 sameAs 2051223449 @default.
• W2051223449 citedByCount "40" @default.
• W2051223449 countsByYear W20512234492014 @default.
• W2051223449 countsByYear W20512234492015 @default.
• W2051223449 countsByYear W20512234492016 @default.
• W2051223449 countsByYear W20512234492017 @default.
• W2051223449 countsByYear W20512234492018 @default.
• W2051223449 countsByYear W20512234492019 @default.
• W2051223449 countsByYear W20512234492021 @default.
• W2051223449 countsByYear W20512234492022 @default.
• W2051223449 countsByYear W20512234492023 @default.
• W2051223449 crossrefType "journal-article" @default.
• W2051223449 hasAuthorship W2051223449A5002703541 @default.
• W2051223449 hasAuthorship W2051223449A5008547275 @default.
• W2051223449 hasAuthorship W2051223449A5023976873 @default.
• W2051223449 hasAuthorship W2051223449A5032760861 @default.
• W2051223449 hasAuthorship W2051223449A5064081956 @default.
• W2051223449 hasAuthorship W2051223449A5070384778 @default.
• W2051223449 hasAuthorship W2051223449A5070729843 @default.
• W2051223449 hasAuthorship W2051223449A5075201353 @default.
• W2051223449 hasBestOaLocation W20512234491 @default.
• W2051223449 hasConcept C121608353 @default.
• W2051223449 hasConcept C126322002 @default.
• W2051223449 hasConcept C170493617 @default.
• W2051223449 hasConcept C17991360 @default.
• W2051223449 hasConcept C185592680 @default.
• W2051223449 hasConcept C190283241 @default.
• W2051223449 hasConcept C199835354 @default.
• W2051223449 hasConcept C2778019345 @default.
• W2051223449 hasConcept C2778695046 @default.
• W2051223449 hasConcept C2778938600 @default.
• W2051223449 hasConcept C29537977 @default.
• W2051223449 hasConcept C502942594 @default.
• W2051223449 hasConcept C55493867 @default.
• W2051223449 hasConcept C71924100 @default.
• W2051223449 hasConceptScore W2051223449C121608353 @default.
• W2051223449 hasConceptScore W2051223449C126322002 @default.
• W2051223449 hasConceptScore W2051223449C170493617 @default.
• W2051223449 hasConceptScore W2051223449C17991360 @default.
• W2051223449 hasConceptScore W2051223449C185592680 @default.
• W2051223449 hasConceptScore W2051223449C190283241 @default.

• next